Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Locked in a heated battle for I/O supremacy, Merck and Bristol have readily engaged in proxy battles for new indications, tag-teaming their blockbusters with other meds to get a leg up. Now, after already scoring a combo win with another TKI inhibitor in kidney cancer, Merck is holding up promising data for another Keytruda pairing.